Recognition and Management of Resistant Hypertension
- PMID: 27895136
- PMCID: PMC5338706
- DOI: 10.2215/CJN.06180616
Recognition and Management of Resistant Hypertension
Abstract
Despite improvements in hypertension awareness and treatment, 30%-60% of hypertensive patients do not achieve BP targets and subsequently remain at risk for target organ damage. This therapeutic gap is particularly important to nephrologists, who frequently encounter treatment-resistant hypertension in patients with CKD. Data are limited on how best to treat patients with CKD and resistant hypertension, because patients with CKD have historically been excluded from hypertension treatment trials. First, we propose a consistent definition of resistant hypertension as BP levels confirmed by both in-office and out-of-office measurements that exceed appropriate targets while the patient is receiving treatment with at least three antihypertensive medications, including a diuretic, at dosages optimized to provide maximum benefit in the absence of intolerable side effects. Second, we recommend that each patient undergo a standardized, stepwise evaluation to assess adherence to dietary and lifestyle modifications and antihypertensive medications to identify and reduce barriers and discontinue use of substances that may exacerbate hypertension. Patients in whom there is high clinical suspicion should be evaluated for potential secondary causes of hypertension. Evidence-based management of resistant hypertension is discussed with special considerations of the differences in approach to patients with and without CKD, including the specific roles of diuretics and mineralocorticoid receptor antagonists and the current place of emerging therapies, such as renal denervation and baroreceptor stimulation. We endorse use of such a systematic approach to improve recognition and care for this vulnerable patient group that is at high risk for future kidney and cardiovascular events.
Keywords: Antagonists; Antihypertensive Agents; Denervation; Humans; Life Style; Mineralocorticoid Receptor; Pressoreceptors; Renal Insufficiency, Chronic; blood pressure; cardiovascular disease; chronic kidney disease; diuretics; hypertension; kidney; renal denvervation; sodium intake.
Copyright © 2017 by the American Society of Nephrology.
Figures
Similar articles
-
Diagnosis and management of resistant hypertension: state of the art.Nat Rev Nephrol. 2018 Jul;14(7):428-441. doi: 10.1038/s41581-018-0006-6. Nat Rev Nephrol. 2018. PMID: 29700488 Review.
-
Resistant hypertension: medical management and alternative therapies.Cardiol Clin. 2015 Feb;33(1):75-87. doi: 10.1016/j.ccl.2014.09.003. Cardiol Clin. 2015. PMID: 25439332 Review.
-
Apparent treatment-resistant hypertension and chronic kidney disease: another cardiovascular-renal syndrome?Adv Chronic Kidney Dis. 2014 Nov;21(6):489-99. doi: 10.1053/j.ackd.2014.08.006. Epub 2014 Oct 24. Adv Chronic Kidney Dis. 2014. PMID: 25443574 Review.
-
Resistant Hypertension in People With CKD: A Review.Am J Kidney Dis. 2021 Jan;77(1):110-121. doi: 10.1053/j.ajkd.2020.04.017. Epub 2020 Jul 23. Am J Kidney Dis. 2021. PMID: 32712185 Review.
-
Role of sodium restriction and diuretic therapy for "resistant" hypertension in chronic kidney disease.Semin Nephrol. 2014;34(5):514-9. doi: 10.1016/j.semnephrol.2014.08.005. Semin Nephrol. 2014. PMID: 25416660 Review.
Cited by
-
Dietary sodium restriction reduces blood pressure in patients with treatment resistant hypertension.BMC Nephrol. 2023 Sep 19;24(1):274. doi: 10.1186/s12882-023-03333-9. BMC Nephrol. 2023. PMID: 37726656 Free PMC article.
-
Beyond Conventional Control: Insights Into Drug-Resistant Hypertension.Cureus. 2023 Aug 17;15(8):e43617. doi: 10.7759/cureus.43617. eCollection 2023 Aug. Cureus. 2023. PMID: 37719515 Free PMC article. Review.
-
Results of the trycort: Cohort study of add-on antihypertensives for treatment of resistant hypertension.Medicine (Baltimore). 2023 Jun 2;102(22):e33941. doi: 10.1097/MD.0000000000033941. Medicine (Baltimore). 2023. PMID: 37266607 Free PMC article.
-
Novel Dual Endothelin Inhibitors in the Management of Resistant Hypertension.Life (Basel). 2023 Mar 16;13(3):806. doi: 10.3390/life13030806. Life (Basel). 2023. PMID: 36983961 Free PMC article. Review.
-
Cardiac structure and function in resistant hypertension: The beneficial role of blood pressure control.J Clin Hypertens (Greenwich). 2023 May;25(5):426-428. doi: 10.1111/jch.14626. Epub 2023 Mar 2. J Clin Hypertens (Greenwich). 2023. PMID: 36861493 Free PMC article. No abstract available.
References
-
- Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM; American Heart Association Professional Education Committee : Resistant hypertension: Diagnosis, evaluation, and treatment:A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 117: e510–e526, 2008 - PubMed
-
- Weitzman D, Chodick G, Shalev V, Grossman C, Grossman E: Prevalence and factors associated with resistant hypertension in a large health maintenance organization in Israel. Hypertension 64: 501–507, 2014 - PubMed
-
- Gifford RW, Jr.: Resistant hypertension. Introduction and definitions. Hypertension 11: II65–II66, 1988 - PubMed
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
